Pliant Therapeutics (PLRX) director files initial insider ownership statement

Rhea-AI Filing Summary

Pliant Therapeutics, Inc. director Borellini Flavia has filed an initial statement of beneficial ownership as a reporting person. The filing lists her status as a director of the company and reports no equity transactions or derivative positions, providing an initial disclosure of her insider status without detailing current holdings.

Key Figures

Buy transactions reported: 0 Sell transactions reported: 0 Derivative transactions reported: 0

3 metrics

Buy transactions reported 0 BuyCount in transaction summary of initial ownership statement

Sell transactions reported 0 SellCount in transaction summary of initial ownership statement

Derivative transactions reported 0 derivativeTransactionCount in transaction summary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/13/2026 - 04:32 PM Accepted by SEC EDGAR 07/13/2026 - 04:32 PM Learn about SEC filing dates

FAQ

What does the PLRX Form 3 filing by Borellini Flavia report?

The Form 3 for Pliant Therapeutics (PLRX) reports that Borellini Flavia is a director and serves as a reporting insider. It shows no reported equity transactions or derivative positions in this initial ownership statement.

Does the PLRX Form 3 show any stock purchases or sales by Borellini Flavia?

No. The Form 3 for Pliant Therapeutics (PLRX) shows zero buy, sell, acquire, or dispose transactions. It functions purely as an initial insider ownership and status disclosure without trade activity.

What insider role does Borellini Flavia have at Pliant Therapeutics (PLRX)?

Borellini Flavia is identified as a director of Pliant Therapeutics, Inc. in the Form 3. She is not listed as an officer or a ten percent owner in this filing.

Are there any derivative securities reported in the PLRX Form 3?

No. The Form 3 for Pliant Therapeutics (PLRX) shows an empty derivative summary and a derivative transaction count of zero, indicating no options, warrants, or similar instruments are reported in this initial filing.

Does the PLRX Form 3 indicate net buying or selling by the reporting person?

No. The transaction summary shows netBuySellDirection as "neutral" with zero buy, sell, and exercise shares, indicating no reported trading activity in this initial statement.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Borellini Flavia

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/09/2026

3. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 Power of Attorney

No securities are beneficially owned.

	/s/ Jennifer Woo, attorney-in-fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)